Transcript
-
Crohn
1
1
2
1/- 4 2
-
Crohn
( )
,
: 20-30 60-70
-
-
-
Bowel rest
-
Anti-TNF
Infliximab
Adalimumab
Certolizumab pegol
Anti-integrin 4 Vedolizumab
Natalizumab
-
Infliximab
EMA approval: 1999
mAb IgG1 -
:
Crohn
-
:
, ,
:
, , , , ,
-
Adalimumab
EMA approval: 2003
mAb IgG1
TNF
:
Crohn
-
:
infliximab
:
, , , -, , ,
-
Certolizumab pegol
FDA approval: 2008
-
- (Kawalek et al, 2013)
-
The role of selected integrinsin lymphocyte migration
-
Natalizumab
FDA approval: 2008
-4
PML (JC virus) EMA
MS
-
Vedolizumab
EMA approval: 2014
mAb IgG1 -47
-
:
Crohn, anti-TNF ( )
-
:
,
:
, ,
-
CD + UC = IBD
anti-TNF anti-integrin 4 nti-TNF: infliximab, adalimumab
Anti-integrin 4: vedolizumab